RecruitingPhase 4NCT06878482
Effect of Blood Flow by Botulinum Toxin Injection for Severe Peripheral Artery Occlusive Disease
Effect of Increasing Blood Flow by Botulinum Toxin Local Injection for Severe Peripheral Artery Occlusive Disease: Preliminary Report
Sponsor
Yonsei University
Enrollment
15 participants
Start Date
Apr 17, 2023
Study Type
INTERVENTIONAL
Conditions
Summary
The purpose of this study is to investigate the effect of subcutaneous injection of botulinum toxin A on wound healing caused by lower extremity ischemia.
Eligibility
Min Age: 20 Years
Inclusion Criteria6
- Age ≥ 20 years old
- Patients who have a lower extremity wound among those who have been diagnosed with moderate or severe lower extremity ischemia
- Patients who are unable to perform additional procedures (angioplasty, etc.) by performing peripheral vascular examination and CT angiography
- Wound size ≥ 1x1cm2 to ≤ 3x3cm2
- Patients who can follow the clinical trial procedure well and abide by the visit schedule
- Written informed consent to participate in the study after having fully understood the contents of the protocol and restrictions.
Exclusion Criteria12
- Patients with diseases that can affect neuromuscular function, such as myasthenia gravis, Eaton-Lamberton syndrome, amyotrophic lateral sclerosis, and motor neuropathy
- Within 4 weeks before screening, aminoglycoside antibiotics, curare-like agents, or drugs that inhibit neuromuscular function (muscle relaxants, anticholinergics, benzodiazepines, benzamides, tetracyclines, Rinco Those who have taken mycin antibiotics, etc.)
- Those taking aspirin, NSAIDs or anticoagulants within 7 days before screening
- Those who have received botulinum toxin preparations within 3 months before screening
- Angiography or CT angiography If one or more of the three major blood vessels in the lower extremity are open
- Cases in which blood flow to the lower extremities can be preserved by performing balloon angioplasty even if all three major blood vessels in the lower extremity are blocked
- Those who are currently taking steroids or immunosuppressants that affect wounds, or those who have taken them within one month of screening
- Those who have applied injection drugs or wound coverings that help improve wounds within 1 week of screening
- Women who are pregnant, lactating, planning to become pregnant during the clinical period, or women of childbearing age who are not using available contraceptive methods (women of childbearing age must be negative in the pregnancy test prior to injection).
- Those who are allergic or sensitive to botulinum toxin
- Those who have participated in another clinical trial within 30 days before screening or those who have not passed the half-life of the investigational product of the clinical trial that they participated in, whichever is longer.
- Those who are not suitable for this clinical trial under the judgment of other investigators
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
DRUGBotulinum toxin A
subcutaneous injection of Botulinum toxin A
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06878482
Related Trials
A Study of NT 201 in Adults With Moderate to Severe Platysma Prominence in Europe (PLATINUM EU)
NCT0721046326 locations
Electric Stimulation Home Use(CGM MEPC_2401) for Improving Blood Circulation
NCT074460881 location
A Study Evaluating the Safety and Efficacy of the 3M™ V.A.C. Peel and Place Dressing
NCT066253853 locations
Miro3D Randomized Controlled Trial (RCT)
NCT073471061 location
A Study of NT 201 in Adults With Moderate to Severe Platysma Prominence in the United States
NCT0712219328 locations